Current approaches to the diagnostics and treatment of acromegaly


DOI: https://dx.doi.org/10.18565/pharmateca.2019.4.100-104

M.B. Antsiferov (1), T.M. Alekseeva (1), A.V. Andreeva (2)

1) Endocrinological Dispensary of the Moscow Healthcare Department, Russia; 2) V.V. Veresaev City Clinical Hospital, Moscow Healthcare Department, Russia

Acromegaly is a severe chronic neuroendocrine disease that requires timely, adequate diagnosis and therapy. In the diagnosis of acromegaly, determination of the insulin-like growth factor-1 and growth hormone levels, as well as neuroimaging, play a key role. In the treatment of acromegaly, surgery is the best choice. In the absence of ability of surgical intervention or in the case of non-radicality of the surgical treatment, the pharmacotherapy is indicated. Somatostatin analogues (SSA) today are the most effective means of drug control of secretory and proliferative tumor activity. In the case of resistance to SSA, it is possible to transfer to another SSA, increase the dose of SSA, or add dopamine agonists and growth hormone receptor antagonists to the SSA.


For citations: Antsiferov M.B., Alekseeva T.M., Andreeva A.V. Current approaches to the diagnostics and treatment of acromegaly. Farmateka. 2019;26(4):100–4. (in Russian). DOI: https://dx.doi.org/10.18565/pharmateca.2019.4.100-104 


About the Autors


Corresponding author: Mikhail B. Antsiferov, MD, Professor, Chief Physician of the Endocrinological Dispensary of the Moscow Healthcare Department, Moscow, Russia; e-mail: antsiferov@rambler.ru; ORCID: http://orcid.com/0000-0002-9944-2997; eLibrary SPIN: 1035–4773; Address: 37, Prechistenka Street, Moscow 119034, Russian Federation


Similar Articles


Бионика Медиа